Literature DB >> 10231725

The oncostatic action of melatonin in an ovarian carcinoma cell line.

J Petranka1, W Baldwin, J Biermann, S Jayadev, J C Barrett, E Murphy.   

Abstract

Melatonin is reported to reduce proliferation in many cell types, but the effect is small and the results are inconsistent. Information on the mechanism by which melatonin exerts its antiproliferative effects might provide insight into the variability of the response. In an ovarian adenocarcinoma cell line (BG-1), we find that melatonin at concentrations of 10(-9)-10(-7) M caused a 20-25% reduction in cell number. Melatonin also resulted in a similar reduction in [3H]-thymidine incorporation with no significant increase in cell death as measured by trypan blue incorporation. The Kd for melatonin reduction in cell number was approximately 5 x 10(-10) M. Melatonin ML2 receptors have a Kd for melatonin binding in the low nM range and are linked to the production of the calcium mobilizing agent inositol-1,4,5-trisphosphate (IP3). To investigate whether melatonin signaling involves an increase in cytosolic-free calcium. BG-1 cells were loaded with the calcium sensitive indicator, fura-2. Acute addition of melatonin (10(-5)-10(-9) M) did not alter cytosolic calcium. Addition of the putative nuclear receptor agonist CGP52608 caused a dose-dependent inhibition of cell number with a Kd of approximately 2 x 10(-9) M. Addition of CGP52608 caused a similar reduction in [3H]-thymidine incorporation. Neither melatonin (10(-8) M-10(-5) M) nor CGP52608 at concentrations below 10(-7) M induced cell death associated with the inhibition of cell proliferation; however, addition of CGP52608 at a high dose (10(-7) M) caused an increase in cell death, consistent with apoptosis. Growth inhibition by melatonin or CGP52608 did not alter the percentage of cells in G1 versus S/G2/M.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10231725     DOI: 10.1111/j.1600-079x.1999.tb00574.x

Source DB:  PubMed          Journal:  J Pineal Res        ISSN: 0742-3098            Impact factor:   13.007


  18 in total

Review 1.  Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer.

Authors:  Brittney Jung-Hynes; Russel J Reiter; Nihal Ahmad
Journal:  J Pineal Res       Date:  2010-01       Impact factor: 13.007

2.  Carcinogen-induced, free radical-mediated reduction in microsomal membrane fluidity: reversal by indole-3-propionic acid.

Authors:  M Karbownik; J J Garcia; A Lewiński; R J Reiter
Journal:  J Bioenerg Biomembr       Date:  2001-02       Impact factor: 2.945

3.  Urinary melatonin and risk of ovarian cancer.

Authors:  Elizabeth M Poole; Eva Schernhammer; Leigha Mills; Susan E Hankinson; Shelley S Tworoger
Journal:  Cancer Causes Control       Date:  2015-07-30       Impact factor: 2.506

4.  Melatonin Synergizes the Chemotherapeutic Effect of Cisplatin in Ovarian Cancer Cells Independently of MT1 Melatonin Receptors.

Authors:  Agata Zemła; Irmina Grzegorek; Piotr Dzięgiel; Karolina Jabłońska
Journal:  In Vivo       Date:  2017 Sep-Oct       Impact factor: 2.155

Review 5.  Neurobiology, pathophysiology, and treatment of melatonin deficiency and dysfunction.

Authors:  Rüdiger Hardeland
Journal:  ScientificWorldJournal       Date:  2012-05-02

6.  Expression of the MT1 melatonin receptor in ovarian cancer cells.

Authors:  Karolina Jablonska; Bartosz Pula; Agata Zemla; Christopher Kobierzycki; Witold Kedzia; Ewa Nowak-Markwitz; Marek Spaczynski; Maciej Zabel; Marzenna Podhorska-Okolow; Piotr Dziegiel
Journal:  Int J Mol Sci       Date:  2014-12-12       Impact factor: 5.923

7.  Melatonin attenuates the TLR4-mediated inflammatory response through MyD88- and TRIF-dependent signaling pathways in an in vivo model of ovarian cancer.

Authors:  Luiz Gustavo A Chuffa; Beatriz A Fioruci-Fontanelli; Leonardo O Mendes; Fábio R Ferreira Seiva; Marcelo Martinez; Wagner J Fávaro; Raquel F Domeniconi; Patrícia F F Pinheiro; Lucilene Delazari Dos Santos; Francisco Eduardo Martinez
Journal:  BMC Cancer       Date:  2015-02-06       Impact factor: 4.430

8.  Melatonin inhibits gallbladder cancer cell migration and invasion via ERK-mediated induction of epithelial-to-mesenchymal transition.

Authors:  Hongwei Tang; Xiaoyi Shi; Pengfei Zhu; Wenzhi Guo; Jie Li; Bing Yan; Shuijun Zhang
Journal:  Oncol Lett       Date:  2021-06-15       Impact factor: 2.967

9.  Melatonin induces transcriptional regulation of Bim by FoxO3a in HepG2 cells.

Authors:  S Carbajo-Pescador; C Steinmetz; A Kashyap; S Lorenz; J L Mauriz; M Heise; P R Galle; J González-Gallego; S Strand
Journal:  Br J Cancer       Date:  2012-12-20       Impact factor: 7.640

Review 10.  Melatonin and cancer risk: does light at night compromise physiologic cancer protection by lowering serum melatonin levels?

Authors:  E S Schernhammer; K Schulmeister
Journal:  Br J Cancer       Date:  2004-03-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.